Skip to content

Study · Randomized controlled trial · n = 36 · 2007

10 results

Effect of 5 days linaclotide on transit and bowel function in females with constipation-predominant irritable bowel syndrome.

Andresen V, Camilleri M, Busciglio IA, Grudell A, Burton D, McKinzie S, Foxx-Orenstein A, Kurtz CB, Sharma V, Johnston JM, Currie MG, Zinsmeister AR

Gastroenterology3 Jul 2007Cited by 178 (Europe PMC)

PMID17854590 (opens in a new tab)DOI10.1053/j.gastro.2007.06.067 (opens in a new tab)PepBankPUB-17854590
Publisher pagePubMedAsk about this study
Jump to 10 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study10

10 results from studies that gave the peptide. 10 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In women with constipation-predominant irritable bowel syndrome, linaclotide had no significant overall treatment effect on transit at 24 hours.

    In plain wordsIn women with constipation-predominant irritable bowel syndrome, linaclotide did not significantly change transit at 24 hours compared with placebo.

    Peptide
    Linaclotide
    Outcome
    No significant changeOverall transit at 24 hours
    Study

    n = 36

    Comparator
    Placebo
    Outcome group
    Bowel Function · Gastrointestinal
    Studied dose
    100 and 1000 microg once daily · oral · 5 daysAs given in this study (human).

    Source sentences

    Summary
    There was a significant overall treatment effect on ascending colon emptying half-time (P = .015) and overall colonic transit at 48 hours (P = .02) but not overall transit at 24 hours (P = ns), with a significant acceleration by linaclotide 1000 microg vs placebo (P = .004 and P = .01, respectively)…
    2 context sentences
    Summary · context
    This randomized, double-blind, placebo-controlled study evaluated the effects of oral linaclotide, 100 and 1000 microg once daily, in 36 women with constipation-predominant irritable bowel syndrome; colonic transit was normal in >50% patients.
    Summary · context
    Participants underwent 5-day baseline and 5-day treatment periods; gastrointestinal transit (by validated scintigraphy) and bowel function (by daily diaries) were assessed.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In women with constipation-predominant irritable bowel syndrome, linaclotide had a significant overall treatment effect on stool frequency.

    In plain wordsIn women with constipation-predominant irritable bowel syndrome, linaclotide changed stool frequency compared with placebo.

    Peptide
    Linaclotide
    Outcome
    Direction not reportedStool frequency
    Study

    n = 36

    Comparator
    Placebo
    Outcome group
    Bowel Function · Gastrointestinal
    Studied dose
    100 and 1000 microg once daily · oral · 5 daysAs given in this study (human).

    Source sentences

    Summary
    There were significant overall treatment effects on stool frequency, stool consistency, ease of passage, and time to first bowel movement with a strong dose response for stool consistency (overall, P < .001).
    2 context sentences
    Summary · context
    This randomized, double-blind, placebo-controlled study evaluated the effects of oral linaclotide, 100 and 1000 microg once daily, in 36 women with constipation-predominant irritable bowel syndrome; colonic transit was normal in >50% patients.
    Summary · context
    Participants underwent 5-day baseline and 5-day treatment periods; gastrointestinal transit (by validated scintigraphy) and bowel function (by daily diaries) were assessed.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In women with constipation-predominant irritable bowel syndrome, linaclotide affected stool consistency with a strong dose response (overall, P < .001).

    In plain wordsIn women with constipation-predominant irritable bowel syndrome, linaclotide changed stool consistency compared with placebo, with a strong dose response.

    Peptide
    Linaclotide
    Outcome
    Direction not reportedStool consistency
    Study

    n = 36

    Comparator
    Placebo
    Outcome group
    Bowel Function · Gastrointestinal
    Studied dose
    100 and 1000 microg once daily · oral · 5 daysAs given in this study (human).

    Source sentences

    Summary
    There were significant overall treatment effects on stool frequency, stool consistency, ease of passage, and time to first bowel movement with a strong dose response for stool consistency (overall, P < .001).
    2 context sentences
    Summary · context
    This randomized, double-blind, placebo-controlled study evaluated the effects of oral linaclotide, 100 and 1000 microg once daily, in 36 women with constipation-predominant irritable bowel syndrome; colonic transit was normal in >50% patients.
    Summary · context
    Participants underwent 5-day baseline and 5-day treatment periods; gastrointestinal transit (by validated scintigraphy) and bowel function (by daily diaries) were assessed.
  4. 04HumanRandomized controlled trialEfficacy outcome

    In women with constipation-predominant irritable bowel syndrome, linaclotide had a significant overall treatment effect on ease of passage.

    In plain wordsIn women with constipation-predominant irritable bowel syndrome, linaclotide changed ease of stool passage compared with placebo.

    Peptide
    Linaclotide
    Outcome
    Direction not reportedEase of passage
    Study

    n = 36

    Comparator
    Placebo
    Outcome group
    Bowel Function · Gastrointestinal
    Studied dose
    100 and 1000 microg once daily · oral · 5 daysAs given in this study (human).

    Source sentences

    Summary
    There were significant overall treatment effects on stool frequency, stool consistency, ease of passage, and time to first bowel movement with a strong dose response for stool consistency (overall, P < .001).
    2 context sentences
    Summary · context
    This randomized, double-blind, placebo-controlled study evaluated the effects of oral linaclotide, 100 and 1000 microg once daily, in 36 women with constipation-predominant irritable bowel syndrome; colonic transit was normal in >50% patients.
    Summary · context
    Participants underwent 5-day baseline and 5-day treatment periods; gastrointestinal transit (by validated scintigraphy) and bowel function (by daily diaries) were assessed.
  5. 05HumanRandomized controlled trialEfficacy outcome

    In women with constipation-predominant irritable bowel syndrome, linaclotide had a significant overall treatment effect on time to first bowel movement.

    In plain wordsIn women with constipation-predominant irritable bowel syndrome, linaclotide changed time to first bowel movement compared with placebo.

    Peptide
    Linaclotide
    Outcome
    Direction not reportedTime to first bowel movement
    Study

    n = 36

    Comparator
    Placebo
    Outcome group
    Bowel Function · Gastrointestinal
    Studied dose
    100 and 1000 microg once daily · oral · 5 daysAs given in this study (human).

    Source sentences

    Summary
    There were significant overall treatment effects on stool frequency, stool consistency, ease of passage, and time to first bowel movement with a strong dose response for stool consistency (overall, P < .001).
    2 context sentences
    Summary · context
    This randomized, double-blind, placebo-controlled study evaluated the effects of oral linaclotide, 100 and 1000 microg once daily, in 36 women with constipation-predominant irritable bowel syndrome; colonic transit was normal in >50% patients.
    Summary · context
    Participants underwent 5-day baseline and 5-day treatment periods; gastrointestinal transit (by validated scintigraphy) and bowel function (by daily diaries) were assessed.
  6. 06HumanRandomized controlled trialEfficacy outcome

    In women with constipation-predominant irritable bowel syndrome, linaclotide 1000 microg accelerated ascending colon emptying versus placebo (P = .004).

    In plain wordsIn women with constipation-predominant irritable bowel syndrome, linaclotide accelerated ascending colon emptying compared with placebo.

    Peptide
    Linaclotide
    Outcome
    DecreaseAscending colon emptying half-time
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Bowel Function · Gastrointestinal
    Studied dose
    1000 microg once daily · oral · 5 daysAs given in this study (human).

    Source sentences

    Summary
    There was a significant overall treatment effect on ascending colon emptying half-time (P = .015) and overall colonic transit at 48 hours (P = .02) but not overall transit at 24 hours (P = ns), with a significant acceleration by linaclotide 1000 microg vs placebo (P = .004 and P = .01, respectively)…
    2 context sentences
    Summary · context
    This randomized, double-blind, placebo-controlled study evaluated the effects of oral linaclotide, 100 and 1000 microg once daily, in 36 women with constipation-predominant irritable bowel syndrome; colonic transit was normal in >50% patients.
    Summary · context
    Participants underwent 5-day baseline and 5-day treatment periods; gastrointestinal transit (by validated scintigraphy) and bowel function (by daily diaries) were assessed.
  7. 07HumanRandomized controlled trialEfficacy outcome

    In women with constipation-predominant irritable bowel syndrome, linaclotide 1000 microg accelerated colonic transit at 48 hours versus placebo (P = .01).

    In plain wordsIn women with constipation-predominant irritable bowel syndrome, linaclotide accelerated colonic transit compared with placebo.

    Peptide
    Linaclotide
    Outcome
    IncreaseColonic transit at 48 hours
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Bowel Function · Gastrointestinal
    Studied dose
    1000 microg once daily · oral · 5 daysAs given in this study (human).

    Source sentences

    Summary
    There was a significant overall treatment effect on ascending colon emptying half-time (P = .015) and overall colonic transit at 48 hours (P = .02) but not overall transit at 24 hours (P = ns), with a significant acceleration by linaclotide 1000 microg vs placebo (P = .004 and P = .01, respectively)…
    2 context sentences
    Summary · context
    This randomized, double-blind, placebo-controlled study evaluated the effects of oral linaclotide, 100 and 1000 microg once daily, in 36 women with constipation-predominant irritable bowel syndrome; colonic transit was normal in >50% patients.
    Summary · context
    Participants underwent 5-day baseline and 5-day treatment periods; gastrointestinal transit (by validated scintigraphy) and bowel function (by daily diaries) were assessed.
  8. 08HumanRandomized controlled trialEfficacy outcome

    In women with constipation-predominant irritable bowel syndrome, linaclotide 100 microg had no significant effect on ascending colon emptying versus placebo.

    In plain wordsIn women with constipation-predominant irritable bowel syndrome, low-dose linaclotide did not significantly change ascending colon emptying compared with placebo.

    Peptide
    Linaclotide
    Outcome
    No significant changeAscending colon emptying half-time
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Bowel Function · Gastrointestinal
    Studied dose
    100 microg once daily · oral · 5 daysAs given in this study (human).

    Source sentences

    Summary
    There was a significant overall treatment effect on ascending colon emptying half-time (P = .015) and overall colonic transit at 48 hours (P = .02) but not overall transit at 24 hours (P = ns), with a significant acceleration by linaclotide 1000 microg vs placebo (P = .004 and P = .01, respectively)…
    2 context sentences
    Summary · context
    This randomized, double-blind, placebo-controlled study evaluated the effects of oral linaclotide, 100 and 1000 microg once daily, in 36 women with constipation-predominant irritable bowel syndrome; colonic transit was normal in >50% patients.
    Summary · context
    Participants underwent 5-day baseline and 5-day treatment periods; gastrointestinal transit (by validated scintigraphy) and bowel function (by daily diaries) were assessed.
  9. 09HumanRandomized controlled trialEfficacy outcome

    In women with constipation-predominant irritable bowel syndrome, linaclotide 100 microg had no significant effect on colonic transit at 48 hours versus placebo.

    In plain wordsIn women with constipation-predominant irritable bowel syndrome, low-dose linaclotide did not significantly change colonic transit compared with placebo.

    Peptide
    Linaclotide
    Outcome
    No significant changeColonic transit at 48 hours
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Bowel Function · Gastrointestinal
    Studied dose
    100 microg once daily · oral · 5 daysAs given in this study (human).

    Source sentences

    Summary
    There was a significant overall treatment effect on ascending colon emptying half-time (P = .015) and overall colonic transit at 48 hours (P = .02) but not overall transit at 24 hours (P = ns), with a significant acceleration by linaclotide 1000 microg vs placebo (P = .004 and P = .01, respectively)…
    2 context sentences
    Summary · context
    This randomized, double-blind, placebo-controlled study evaluated the effects of oral linaclotide, 100 and 1000 microg once daily, in 36 women with constipation-predominant irritable bowel syndrome; colonic transit was normal in >50% patients.
    Summary · context
    Participants underwent 5-day baseline and 5-day treatment periods; gastrointestinal transit (by validated scintigraphy) and bowel function (by daily diaries) were assessed.
  10. 10HumanNon-randomized trialSafety outcome

    In women with constipation-predominant irritable bowel syndrome treated with linaclotide, no safety issues were identified.

    In plain wordsIn women with constipation-predominant irritable bowel syndrome treated with linaclotide, researchers identified no safety issues.

    Peptide
    Linaclotide
    Outcome
    Direction not reportedSafety issues
    Study

    n: not reported in source

    Outcome group
    Adverse events · Whole body
    Studied dose
    100 and 1000 microg once daily · oral · 5 daysAs given in this study (human).

    Source sentences

    Summary
    No safety issues were identified.
    2 context sentences
    Summary · context
    This randomized, double-blind, placebo-controlled study evaluated the effects of oral linaclotide, 100 and 1000 microg once daily, in 36 women with constipation-predominant irritable bowel syndrome; colonic transit was normal in >50% patients.
    Summary · context
    Participants underwent 5-day baseline and 5-day treatment periods; gastrointestinal transit (by validated scintigraphy) and bowel function (by daily diaries) were assessed.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:34 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.